Literature DB >> 32240355

[Small molecules and biologicals].

J Smolen1.   

Abstract

Mesh：

Substances：

Year:  2020        PMID： 32240355     DOI： 10.1007/s00393-020-00780-9

Source DB:  PubMed          Journal:  Z Rheumatol        ISSN： 0340-1855            Impact factor:   1.372


× No keyword cloud information.
  29 in total

1.  Baricitinib versus Placebo or Adalimumab in Rheumatoid Arthritis.

Authors:  Peter C Taylor; Edward C Keystone; Désirée van der Heijde; Michael E Weinblatt; Liliana Del Carmen Morales; Jaime Reyes Gonzaga; Sergey Yakushin; Taeko Ishii; Kahaku Emoto; Scott Beattie; Vipin Arora; Carol Gaich; Terence Rooney; Douglas Schlichting; William L Macias; Stephanie de Bono; Yoshiya Tanaka
Journal:  N Engl J Med       Date:  2017-02-16       Impact factor: 91.245

2.  A phase III, randomized, placebo-controlled study of belimumab, a monoclonal antibody that inhibits B lymphocyte stimulator, in patients with systemic lupus erythematosus.

Authors:  Richard Furie; Michelle Petri; Omid Zamani; Ricard Cervera; Daniel J Wallace; Dana Tegzová; Jorge Sanchez-Guerrero; Andreas Schwarting; Joan T Merrill; W Winn Chatham; William Stohl; Ellen M Ginzler; Douglas R Hough; Z John Zhong; William Freimuth; Ronald F van Vollenhoven
Journal:  Arthritis Rheum       Date:  2011-12

3.  Etanercept in the treatment of psoriatic arthritis and psoriasis: a randomised trial.

Authors:  P J Mease; B S Goffe; J Metz; A VanderStoep; B Finck; D J Burge
Journal:  Lancet       Date:  2000-07-29       Impact factor: 79.321

4.  Therapy of lupus nephritis. Controlled trial of prednisone and cytotoxic drugs.

Authors:  H A Austin; J H Klippel; J E Balow; N G le Riche; A D Steinberg; P H Plotz; J L Decker
Journal:  N Engl J Med       Date:  1986-03-06       Impact factor: 91.245

5.  Efficacy and safety of ustekinumab in patients with active psoriatic arthritis: 1 year results of the phase 3, multicentre, double-blind, placebo-controlled PSUMMIT 1 trial.

Authors:  Iain B McInnes; Arthur Kavanaugh; Alice B Gottlieb; Lluís Puig; Proton Rahman; Christopher Ritchlin; Carrie Brodmerkel; Shu Li; Yuhua Wang; Alan M Mendelsohn; Mittie K Doyle
Journal:  Lancet       Date:  2013-06-13       Impact factor: 79.321

Review 6.  Efficacy of methotrexate in rheumatoid arthritis.

Authors:  M E Weinblatt
Journal:  Br J Rheumatol       Date:  1995-11

7.  Baricitinib for systemic lupus erythematosus: a double-blind, randomised, placebo-controlled, phase 2 trial.

Authors:  Daniel J Wallace; Richard A Furie; Yoshiya Tanaka; Kenneth C Kalunian; Marta Mosca; Michelle A Petri; Thomas Dörner; Mario H Cardiel; Ian N Bruce; Elisa Gomez; Tara Carmack; Amy M DeLozier; Jonathan M Janes; Matthew D Linnik; Stephanie de Bono; Maria E Silk; Robert W Hoffman
Journal:  Lancet       Date:  2018-07-21       Impact factor: 79.321

8.  Dose reduction of baricitinib in patients with rheumatoid arthritis achieving sustained disease control: results of a prospective study.

Authors:  Tsutomu Takeuchi; Mark C Genovese; Boulos Haraoui; Zhanguo Li; Li Xie; Rena Klar; Ana Pinto-Correia; Susan Otawa; Pedro Lopez-Romero; Inmaculada de la Torre; William Macias; Terence P Rooney; Josef S Smolen
Journal:  Ann Rheum Dis       Date:  2018-09-07       Impact factor: 19.103

9.  A head-to-head comparison of the efficacy and safety of ixekizumab and adalimumab in biological-naïve patients with active psoriatic arthritis: 24-week results of a randomised, open-label, blinded-assessor trial.

Authors:  Philip J Mease; Josef S Smolen; Frank Behrens; Peter Nash; Soyi Liu Leage; Lingnan Li; Hasan Tahir; Melinda Gooderham; Eswar Krishnan; Hong Liu-Seifert; Paul Emery; Sreekumar G Pillai; Philip S Helliwell
Journal:  Ann Rheum Dis       Date:  2019-09-28       Impact factor: 19.103

10.  Anti-interleukin-17A monoclonal antibody secukinumab in treatment of ankylosing spondylitis: a randomised, double-blind, placebo-controlled trial.

Authors:  Dominique Baeten; Xenofon Baraliakos; Jürgen Braun; Joachim Sieper; Paul Emery; Désirée van der Heijde; Iain McInnes; Jacob M van Laar; Robert Landewé; Paul Wordsworth; Jürgen Wollenhaupt; Herbert Kellner; Jacqueline Paramarta; Jiawei Wei; Arndt Brachat; Stephan Bek; Didier Laurent; Yali Li; Ying A Wang; Arthur P Bertolino; Sandro Gsteiger; Andrew M Wright; Wolfgang Hueber
Journal:  Lancet       Date:  2013-09-13       Impact factor: 79.321
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.